Childhood cancer survivors over age 50 had a threefold higher mortality risk compared with the general population, primarily ...

After a prostate cancer diagnosis, the way your doctor describes your cancer can help you understand what to expect next.

BLRX READ THE FULL BLRX RESEARCH REPORT BioLineRx Ltd. (NASDAQ:BLRX) reported second quarter 2025 results, producing license revenues of $304,000. Following the transition of commercialization ...

New clinical data reveals promising efficacy of VS-7375, a KRAS G12D inhibitor, in advanced lung cancer, highlighting its ...

Nationally recognized leader in cancer control interventions to strengthen community outreach and advance cancer care at TGH Cancer Institute.

August 14, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL ® siRNA gene silencing technology to ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, ...

August 14, 2025BioLineRx Ltd. misses on earnings expectations. Reported EPS is $-1 EPS, expectations were $-0.35. Operator: ...

IO Biotech plans to meet with the FDA this fall to discuss the data from the phase 3 trial of Cylembio and determine next ...

Most important is anti-blood-clot medicine Eliquis, which is due to lose patent exclusivity in 2026. Eliquis emerged last year as Pfizer’s top-performing drug, having grown rapidly to bring in $7.4bn ...

Breast cancer is the leading cause of cancer-related death in women in Trinidad and Tobago, according to the T&T Ministry of ...

Mike, then 27, thought what he was suffering was harmless. But the CT scan revealed a horrifying illness. He had left it far ...